The progressive degeneration of nigrostriatal neurons leads to depletion of the neurotransmitter dopamine (DA) in Parkinson's disease (PD). The hydrophilicity of DA, hindering its cross of the Blood Brain Barrier, makes impossible its therapeutic administration. This work aims at investigating some physicochemical features of novel Solid Lipid Nanoparticles (SLN) intended to enhance DA brain delivery for PD patients by intranasal administration. For this aim, novel SLN were formulated in the presence of Glycol Chitosan (GCS), and it was found that SLN containing GCS and DA were smaller than DA-loaded SLN, endowed with a slightly positive zeta potential value and, remarkably, incorporated 81 % of the initial DA content. The formulated SLN were accurately characterized by Infrared Spectroscopy in Attenuated Total Reflectance mode (FT-IT/ATR) and Thermogravimetric Analysis (TGA) to highlight SLN solid-state properties as a preliminary step forward biological assay. Overall, in vitro characterization shows that SLN are promising for DA incorporation and stable from a thermal viewpoint. Further studies are in due course to test their potential for PD treatment.

中文翻译：

---

对多巴胺负载的固体脂质纳米颗粒的体外研究。

黑纹状体神经元的进行性退化导致帕金森氏病（PD）中神经递质多巴胺（DA）的消耗。DA的亲水性阻碍了其跨过血脑屏障的作用，使其无法进行治疗性给药。这项工作旨在研究新型固体脂质纳米颗粒（SLN）的一些理化特性，这些新型脂质体内颗粒旨在通过鼻内给药增强PD患者的DA脑传递。为此，在乙二醇壳聚糖（GCS）的存在下配制了新型SLN，发现含有GCS和DA的SLN小于DA负载的SLN，具有稍为正的Zeta电位值，并且明显地掺入了81初始DA含量的百分比。通过衰减全反射模式下的红外光谱（FT-IT / ATR）和热重分析（TGA）对配制的SLN进行了准确的表征，以突出SLN的固态性质，这是向前迈进的生物学分析的第一步。总体而言，体外表征显示SLN有希望用于DA掺入并从热学角度来看是稳定的。适时进行进一步的研究以测试其在PD治疗中的潜力。